Skip to main content
. 2011 Oct 4;5(1):35–42. doi: 10.1007/s12154-011-0067-5

Table 2.

ML and MF for the male rats after MKAC9 treatment

Treatment (mg/kg) Mount latency Mount frequency
Acute treatment Control 3.38 ± 0.287 14.33 ± 0.714
MKAC9-10 1.75 ± 0.313** 17.16 ± 0.477**
MKAC9-20 1.74 ± 0.226** 17.83 ± 0.477**
TAD10 1.43 ± 0.344** 18.33 ± 0.714**

**p < 0.01